Pfizer Canada and BioNTech SE have announced an agreement with the Government of Canada to supply their vaccine candidate against SARS-CoV2, subject to clinical success and Health Canada approval.
Deliveries of the vaccine candidate are planned for over the course of 2021.
The plan is to seek regulatory review as early as October, and manufacture globally up to 100 million doses by the end of 2020, and approximately 1.3 billion doses by the end of 2021